NASDAQ:ACRV

Acrivon Therapeutics (ACRV) Stock Forecast, Price & News

$9.27

-0.29 (-3.03%)

(As of 12:55 PM ET)

Compare

Today's Range: $9.13
▼
$9.40
50-Day Range: $8.95
▼
$12.54
52-Week Range: $8.06
▼
$25.47

Volume: 2,067 shs
Average Volume: 39,506 shs
Market Capitalization: $204.59 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $22.86

Acrivon Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 143.4% Upside
$22.86 Price Target
Short Interest: Bearish
2.80% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.16
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($2.64) to ($3.45) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.89 out of 5 stars

Medical Sector

668th out of 969 stocks

Pharmaceutical Preparations Industry

319th out of 453 stocks

3.5

Analyst's Opinion

Consensus Rating
Acrivon Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $22.86, Acrivon Therapeutics has a forecasted upside of 143.4% from its current price of $9.39.
Amount of Analyst Coverage
Acrivon Therapeutics has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
2.80% of the float of Acrivon Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Acrivon Therapeutics has a short interest ratio ("days to cover") of 24.6, which indicates bearish sentiment.
Change versus previous month
Short interest in Acrivon Therapeutics has recently decreased by 0.03%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Acrivon Therapeutics does not currently pay a dividend.
Dividend Growth
Acrivon Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ACRV.

2.9

News and Social Media Coverage

News Sentiment
Acrivon Therapeutics has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Acrivon Therapeutics this week, compared to 1 article on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Acrivon Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.30% of the stock of Acrivon Therapeutics is held by insiders.
Percentage Held by Institutions
68.54% of the stock of Acrivon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Acrivon Therapeutics are expected to decrease in the coming year, from ($2.64) to ($3.45) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Acrivon Therapeutics is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Acrivon Therapeutics is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Acrivon Therapeutics has a P/B Ratio of 1.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Acrivon Therapeutics (NASDAQ:ACRV) Stock

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.

ACRV Price History

30 days | 90 days | 365 days | Advanced Chart

ACRV Stock News Headlines

September 29, 2023 | finanznachrichten.de

Acrivon Therapeutics, Inc: Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 24, 2023 | americanbankingnews.com

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Consensus Recommendation of "Buy" by Brokerages

October 2, 2023 | PressReach (Ad)

Nuclear Revival Creates Opportunities for Uranium

Uranium companies set to benefit from increased demand for clean energy.

September 19, 2023 | finance.yahoo.com

Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

September 5, 2023 | finance.yahoo.com

Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon’s AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies

August 30, 2023 | finance.yahoo.com

Acrivon Therapeutics to Participate in Two Investor Conferences in September

August 18, 2023 | msn.com

JonesTrading Initiates Coverage of Acrivon Therapeutics (ACRV) with Buy Recommendation

August 17, 2023 | finance.yahoo.com

Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 2, 2023 | PressReach (Ad)

Nuclear Revival Creates Opportunities for Uranium

Uranium companies set to benefit from increased demand for clean energy.

August 11, 2023 | finanznachrichten.de

Acrivon Therapeutics, Inc: Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

August 11, 2023 | finance.yahoo.com

Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

July 20, 2023 | finance.yahoo.com

Acrivon Therapeutics Announces the Appointment of Adam Levy, Ph.D., M.B.A., Experienced Biotech Investor Relations and Strategy Executive, to Senior Vice President and Head, Investor Relations and Corporate Affairs

June 22, 2023 | finance.yahoo.com

Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors

June 15, 2023 | benzinga.com

Acrivon Therapeutics 10% Owner Trades Company's Stock

June 2, 2023 | finance.yahoo.com

Acrivon Therapeutics to Present at the Jefferies Healthcare Conference

May 10, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Their Buy Rating for Acrivon Therapeutics, Inc. (ACRV)

May 9, 2023 | finance.yahoo.com

Q1 2023 Akoya Biosciences Inc Earnings Call

May 9, 2023 | finanznachrichten.de

Acrivon Therapeutics, Inc: Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

May 9, 2023 | finance.yahoo.com

Acrivon Therapeutics Announces FDA Grants Fast Track Designation for Development of ACR-368 in Platinum-Resistant Ovarian Cancer and Endometrial Cancer

May 9, 2023 | finance.yahoo.com

Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

May 9, 2023 | markets.businessinsider.com

Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from BMO Capital

May 7, 2023 | finance.yahoo.com

We Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business Growth

May 3, 2023 | msn.com

HC Wainwright & Co. Reiterates Acrivon Therapeutics (ACRV) Buy Recommendation

April 25, 2023 | finance.yahoo.com

Acrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference

April 24, 2023 | finance.yahoo.com

Acrivon Therapeutics to Host Virtual Investor Event on May 1, 2023

April 20, 2023 | msn.com

HC Wainwright & Co. Initiates Coverage of Acrivon Therapeutics (ACRV) with Buy Recommendation

April 18, 2023 | finance.yahoo.com

Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference

See More Headlines

Receive ACRV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACRV Company Calendar

Last Earnings: 8/11/2023
Today: 10/02/2023
Next Earnings (Estimated): 12/21/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ACRV
CUSIP: N/A
CIK: 1781174
Web: www.acrivon.com
Phone: 617-207-8979
Fax: N/A
Employees: 50
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $22.86
High Stock Price Forecast: $26.00
Low Stock Price Forecast: $17.00
Forecasted Upside/Downside: +139.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($7.18)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-31,170,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -41.24%
Return on Assets: -29.91%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 21.84
Quick Ratio: 21.84

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $8.16 per share
Price / Book: 1.17

Miscellaneous

Outstanding Shares: 22,073,000
Free Float: 20,462,000
Market Cap: $211.02 million
Optionable: Not Optionable
Beta: N/A

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Peter Blume-Jensen M.D. (Age 60)
Ph.D., Co-Founder, Chairman, CEO, Pres & Acting Chief Scientific Officer
Comp: $1.01M

Ms. Kristina Masson M.B.A. (Age 42)
Ph.D., Co-Founder, Exec. VP of Bus. Operations, Site Head, Treasurer, Sec. & Director

Mr. Rasmus Holm-Jorgensen (Age 52)
Chief Financial Officer
Comp: $1M

Dr. Eric J. Devroe Ph.D. (Age 45)
Chief Operating Officer
Comp: $614.78k

Ms. Katharine Peterson CPA
VP of Fin. & Accounting

Dr. Adam D. Levy M.B.A.
Ph.D., Sr. VP and Head of Investor Relations & Corp. Affairs

Mr. Bruce Close
VP of Quality & Compliance

Ms. Mary-Alice Miller J.D. (Age 49)
Gen. Counsel

Ms. Parvin Miah
VP & Head of HR

Mr. Erick Gamelin M.D. (Age 66)
Ph.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ACRV Stock - Frequently Asked Questions

Should I buy or sell Acrivon Therapeutics stock right now?: 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acrivon Therapeutics in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ACRV shares.
View ACRV analyst ratings or view top-rated stocks.
What is Acrivon Therapeutics' stock price forecast for 2023?: 9 Wall Street analysts have issued 1 year target prices for Acrivon Therapeutics' stock. Their ACRV share price forecasts range from $17.00 to $26.00. On average, they anticipate the company's share price to reach $22.86 in the next twelve months. This suggests a possible upside of 139.1% from the stock's current price.
View analysts price targets for ACRV or view top-rated stocks among Wall Street analysts.
How have ACRV shares performed in 2023?: Acrivon Therapeutics' stock was trading at $11.52 at the beginning of 2023. Since then, ACRV stock has decreased by 17.0% and is now trading at $9.56.
View the best growth stocks for 2023 here.
When is Acrivon Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, December 21st 2023.
View our ACRV earnings forecast.
How were Acrivon Therapeutics' earnings last quarter?: Acrivon Therapeutics, Inc. (NASDAQ:ACRV) issued its earnings results on Friday, August, 11th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.02.
What ETF holds Acrivon Therapeutics' stock ?: Range Cancer Therapeutics ETF holds 10,409 shares of ACRV stock, representing 1.23% of its portfolio.

When did Acrivon Therapeutics IPO?: (ACRV) raised $100 million in an IPO on Tuesday, November 15th 2022. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley, Jefferies, Cowen and Piper Sandler acted as the underwriters for the IPO.
What is Acrivon Therapeutics' stock symbol?: Acrivon Therapeutics trades on the NASDAQ under the ticker symbol "ACRV."
How do I buy shares of Acrivon Therapeutics?: Shares of ACRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Acrivon Therapeutics' stock price today?: One share of ACRV stock can currently be purchased for approximately $9.56.
How much money does Acrivon Therapeutics make?: Acrivon Therapeutics (NASDAQ:ACRV) has a market capitalization of $211.02 million. The company earns $-31,170,000.00 in net income (profit) each year or ($7.18) on an earnings per share basis.
How can I contact Acrivon Therapeutics?: The official website for the company is www.acrivon.com. The company can be reached via phone at 617-207-8979 or via email at asantos@wheelhouselsa.com.

This page (NASDAQ:ACRV) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Acrivon Therapeutics (ACRV) Stock Forecast, Price & News

Acrivon Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Company Ownership

Earnings and Valuation

About Acrivon Therapeutics (NASDAQ:ACRV) Stock

ACRV Price History

ACRV Stock News Headlines

ACRV Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ACRV Stock - Frequently Asked Questions

Overall MarketRank^™